Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. (“AstraZeneca”) to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. The production agreement is part of AstraZeneca’s recently announced in-licensed program with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit during the COVID-19 pandemic.

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate
Manufacture of COVID-19 vaccine candidate. Image Credit: Carl Recine, Reuters

Cobra hit the ground running with AstraZeneca and other manufacturing organisations to provide large scale manufacturing capacity of AZD1222 vaccine. Cobra, along with other consortium members, will be manufacturing the vaccine with first deliveries to begin in the UK in September 2020.

The agreement is a further development of Cobra’s announcement in March 2020, that the Company is working as part of a consortium with the Jenner Institute, University of Oxford, and others, to rapidly develop, scale-up and produce the recombinant adenovirus vector ChAdOx1 nCoV-19.

I am extremely proud of the contribution made by the Cobra team alongside our consortium partners and despite the current restrictive requirements in place, the progress being made with demanding timelines is outstanding. Cobra’s considerable expertise in GMP viral vector scale up and manufacture will be critical to a successful manufacturing campaign. The agreement with AstraZeneca comes at an opportune time for us as we bring three additional viral vector suites online as part of our ongoing advanced therapies expansion program.”

Peter Coleman, Chief Executive at Cobra Biologics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AstraZeneca. (2020, June 17). Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20200617/Cobra-and-AstraZeneca-sign-supply-agreement-for-manufacture-of-COVID-19-vaccine-candidate.aspx.

  • MLA

    AstraZeneca. "Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20200617/Cobra-and-AstraZeneca-sign-supply-agreement-for-manufacture-of-COVID-19-vaccine-candidate.aspx>.

  • Chicago

    AstraZeneca. "Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate". News-Medical. https://www.news-medical.net/news/20200617/Cobra-and-AstraZeneca-sign-supply-agreement-for-manufacture-of-COVID-19-vaccine-candidate.aspx. (accessed June 16, 2024).

  • Harvard

    AstraZeneca. 2020. Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20200617/Cobra-and-AstraZeneca-sign-supply-agreement-for-manufacture-of-COVID-19-vaccine-candidate.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes